RxDoctor Payments Data

Tashia Adkins Sharrer

Family · Coshocton, OHNPI 1033771720

Payments from drug & device makers

$1,399in general payments, 2019–2025

Across 88 payments — averaging $15.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$251
  • Pfizer$206
  • Exact Sciences$198
  • Novo Nordisk$89
  • Biohaven Pharmaceutical Holding Company Ltd.$88
  • AstraZeneca$87
  • plus $481 from 14 others

What the payments were for

  • Food & beverage$1,399100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,399 in reported general payments places this provider in the 75th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$2,716
Medicare patients
104
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide84$85,721
JardianceEmpagliflozin83$83,553
EliquisApixaban42$45,256
FarxigaDapagliflozin Propanediol42$43,117
OzempicSemaglutide30$36,501
MounjaroTirzepatide33$34,175
RybelsusSemaglutide23$28,707
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$26,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,445
XareltoRivaroxaban26$23,483
Aimovig AutoinjectorErenumab-Aooe14$14,483
Incruse ElliptaUmeclidinium Bromide19$9,211
LinzessLinaclotide12$6,785
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$5,941
Albuterol Sulfate HfaAlbuterol Sulfate215$5,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$49$83,55383 claims
AstraZenecaFarxiga, Breztri Aerosphere$87$69,54180 claims
Novo NordiskOzempic, Rybelsus$89$65,20953 claims
PfizerEliquis$206$45,25642 claims
GSKTrelegy Ellipta, Incruse Ellipta$58$34,65652 claims
AbbVieLinzess$251$6,78512 claims
MerckDulera$51$4,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,812 family providers in Ohio.

Other family in Coshocton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →